With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.109-01-3,1-Methylpiperazine,as a common compound, the synthetic route is as follows.
Example 11: 4-(4-Methyl-i)il)erazin-1 -vlmethyl)-N-r3-(5-thiophen-3-vl-pvrimidin-2-vlamino)-phenyll- benzamide; 4-Chloromethylbenzoic acid (1.7 g, 10 mmol) and 2.78 mL (20 mmol) of triethylamine in 50 mL of dimethylformamide were stirred with 1.22 mL (11 mmol) of N-methylpiperazine overnight at room temperature. The white solid was collected by vacuum filtration and washed with dichloromethane. The combined filtrates were rotary evaporated to dryness to give 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid. N (5-Thiophen-3-yl-pyrimidin-2-yl)-benzene-1,3-diamine (40 mg, 0.15 mmol), triethylamine (0.112 mL, 0.80 mmol), BOP reagent (265 mg, 0.6 mmol) and 93 mg (0.4 mmol) of 4-(4-methyl-piperazin-1- ylmethyl) -benzoic acid in 1 mL of dimethylformamide were stirred overnight at room temperature. The solvent was evaporated and the residue purified by flash chromatography eluting with dichloromethane:methanol 20: 1 and then dichloromethane:methanol 15:1 to give of 4-(4-methyl-piperazin- 1-ylmethyl)-N [3-(5-thiophen-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide. ‘H-NMR (dimethylsulfoxide-d6) 8 10.11 (s, 1 H), 9.68 (s, 1 H), 8.80 (s, 2H), 7.85 (m, 3H), 7.62 (m, 1 H), 7.57 (m, 1 H), 7.42 (d, 1 H), 7.38 (d, 2H), 7.26 (d, 1 H), 7.18 (m, 1 H), 3.45 (s, 2H), 2.50 (m, 8H), 2.30 (s, 3H). MS (m/z) 485 [M+1].; Example 12: 4-( 4-Methvl-piperazin-1-vlmethvl)-N-r 4-(5-thiophen-3-vl-pvrimidin-2-vlamino )-phenvll- benzamide; 4-Chloromethylbenzoic acid (1.7 g, 10 mmol) and 2.78 mL (20 mmol) of triethylamine in 50 mL of dimethylformamide was stirred with 1.22 mL (11 mmol) of N-methylpiperazine overnight at room temperature. The white solid was collected by vacuum filtration and washed with dichloromethane. The combined filtrates were rotary evaporated to dryness to give 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid. N-(5-Thiophen-3-yl-pyrimidin-2-yl)-benzene-1 ,4-diamine (55 mg, 0.20 mmol), triethylamine (0.112 mL, 0.80 mmol), BOP reagent (265 mg, 0.6 mmol) and 93 mg (0.4 mmol) of 4-(4-methyl-piperazin-1- ylmethyl) -benzoic acid in 1 mL of dimethylformamide were stirred overnight at room temperature. The solvent was evaporated and the residue purified by flash chromatography eluting with dichloromethane:methanol 20: 1 and then dichlormehane:methanol 15: 1 to give 4-(4-methyl-piperazin-1- ylmethyl)-N[4-(5-thiophen-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide. H-NMR (dimethylsulfoxide-d6) 8 10.03 (s, 1 H), 9.65 (s, 1 H), 8.80 (s, 2H), 7.85 (m, 3H), 7.67 (m, 2H), 7.63 (m, 2H), 7.57 (d, 1 H), 7.38 (d, 2H), 3.45 (s, 2H), 2.50 (m, 8H), 2.30 (s, 3H). MS (m/z) 485 [M+1].
109-01-3, As the paragraph descriping shows that 109-01-3 is playing an increasingly important role.
Reference：
Patent; SUGEN, INC.; WO2005/113548; (2005); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics